Barclays PLC Coherus Bio Sciences, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 2,466,305 shares of CHRS stock, worth $2.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,466,305

Previous 2,466,305 -0.0%

Holding current value

$2.71 Million

Previous $2.56 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$0.99 - $1.8 $273,026 - $496,411	275,784 Added 12.59%	2,466,305 $2.56 Million
Q2 2024 Aug 14, 2024	BUY	$1.58 - $2.51 $197,768 - $314,176	125,170 Added 6.06%	2,190,521 $3.79 Million
Q1 2024 May 15, 2024	SELL	$2.02 - $3.14 $2.87 Million - $4.46 Million	-1,419,044 Reduced 40.73%	2,065,351 $4.94 Million
Q4 2023 Feb 15, 2024	BUY	$1.59 - $3.85 $1.76 Million - $4.27 Million	1,108,838 Added 46.68%	3,484,395 $11.6 Million
Q3 2023 Nov 07, 2023	BUY	$3.74 - $5.45 $8.61 Million - $12.5 Million	2,301,444 Added 3105.32%	2,375,557 $8.88 Million
Q2 2023 Aug 03, 2023	SELL	$3.79 - $8.3 $433,587 - $949,544	-114,403 Reduced 60.69%	74,113 $317,000
Q1 2023 May 04, 2023	SELL	$5.89 - $10.52 $650,786 - $1.16 Million	-110,490 Reduced 36.95%	188,516 $1.29 Million
Q4 2022 Feb 13, 2023	BUY	$5.69 - $10.07 $536,009 - $948,614	94,202 Added 46.0%	299,006 $2.37 Million
Q3 2022 Nov 03, 2022	BUY	$7.17 - $13.87 $1.16 Million - $2.25 Million	162,448 Added 383.53%	204,804 $1.97 Million
Q2 2022 Aug 12, 2022	SELL	$5.86 - $13.23 $70,929 - $160,135	-12,104 Reduced 22.23%	42,356 $308,000
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $461,151 - $692,994	-42,230 Reduced 43.68%	54,460 $705,000
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $561,776 - $674,771	-35,533 Reduced 26.87%	96,690 $1.54 Million
Q3 2021 Nov 09, 2021	BUY	$12.68 - $17.79 $313,918 - $440,427	24,757 Added 23.04%	132,223 $2.13 Million
Q2 2021 Aug 13, 2021	SELL	$12.95 - $15.41 $532,478 - $633,628	-41,118 Reduced 27.67%	107,466 $1.49 Million
Q1 2021 May 13, 2021	SELL	$14.42 - $21.39 $7.13 Million - $10.6 Million	-494,432 Reduced 76.89%	148,584 $2.17 Million
Q4 2020 Feb 11, 2021	BUY	$16.56 - $18.94 $5 Million - $5.71 Million	301,709 Added 88.4%	643,016 $11.2 Million
Q3 2020 Nov 12, 2020	BUY	$17.41 - $19.89 $981,819 - $1.12 Million	56,394 Added 19.79%	341,307 $6.26 Million
Q2 2020 Aug 12, 2020	SELL	$14.43 - $19.16 $1.79 Million - $2.38 Million	-124,055 Reduced 30.33%	284,913 $5.09 Million
Q1 2020 May 13, 2020	BUY	$11.67 - $22.53 $3.9 Million - $7.52 Million	333,856 Added 444.48%	408,968 $6.63 Million
Q4 2019 Feb 10, 2020	SELL	$16.33 - $21.37 $197,723 - $258,747	-12,108 Reduced 13.88%	75,112 $1.35 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $771,234 - $1.11 Million	47,315 Added 118.57%	87,220 $1.77 Million
Q2 2019 Aug 14, 2019	BUY	$13.1 - $22.1 $257,048 - $433,646	19,622 Added 96.74%	39,905 $882,000
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $148,217 - $274,148	17,687 Added 681.32%	20,283 $276,000
Q4 2018 Feb 14, 2019	SELL	$8.65 - $16.28 $665,833 - $1.25 Million	-76,975 Reduced 96.74%	2,596 $23,000
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $822,985 - $1.15 Million	56,954 Added 251.82%	79,571 $1.31 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $125,511 - $213,675	12,245 Added 118.06%	22,617 $317,000
Q1 2018 May 15, 2018	BUY	$9.1 - $13.7 $25,416 - $38,264	2,793 Added 36.85%	10,372 $115,000
Q4 2017 Feb 14, 2018	SELL	$8.35 - $14.4 $8,851 - $15,264	-1,060 Reduced 12.27%	7,579 $67,000
Q3 2017 Nov 14, 2017	BUY	$11.1 - $14.5 $95,892 - $125,265	8,639	8,639 $115,000

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $85.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account